April 22, 2014 / 6:25 PM / 3 years ago

Valeant won't pay whatever it takes for Allergan -CEO

April 22 (Reuters) - Valeant Pharmaceuticals Inc won’t pay whatever it takes to acquire rival Allergan Inc , and it will not turn its bid into an all-cash deal, Valeant Chief Executive Michael Pearson said on Tuesday in New York.

Valeant and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Botox maker Allergan as it seeks to become one of the world’s five biggest drug companies. (Reporting by Bill Berkrot in New York; Writing by Rod Nickel in Winnipeg, Manitoba; Editing by Meredith Mazzilli)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below